Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

Amplification and/or overexpression of the human epidermal growth factor 2 (HER2) oncogene occurs in about 13–15% of invasive breast cancer and triggers breast cancer cell proliferation, survival and metastatic progression. Around half of all breast cancers with HER2 overexpression co-express hormon...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaler, Sonja, Schmidt, Marcus, Roβwag, Sven, Thiede, Gitta, Schad, Arno, Sleeman, Jonathan P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641130/
https://www.ncbi.nlm.nih.gov/pubmed/29069787
http://dx.doi.org/10.18632/oncotarget.20261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641130/
https://www.ncbi.nlm.nih.gov/pubmed/29069787
http://dx.doi.org/10.18632/oncotarget.20261

Ejemplares similares